Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 single-dose subcutaneous GSK4771261 study in healthy adults
NL-OMON61106Phase 1Suspended
- Sponsor
- GSK
- Start
- May 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, single-arm trial of GSK4771261 in autosomal dominant polycystic kidney disease (ADPKD), sponsored by GSK. Started May 2026; status: suspended.
02
Drugs
GSK4771261
03
Conditions
autosomal dominant polycystic kidney disease (ADPKD)
Beyond the preview
Go deeper on NL-OMON61106.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61106.